Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer
This is a randomised, double-blinded, placebo-controlled, multi-center phase III trial, comparing the efficacy and safety of treatment with Camrelizumab (SHR-1210) + definitive chemoradiotherapy(dCRT) vs placebo+dCRT for locally advanced esophageal cancer patients in China. Camrelizumab (SHR-1210) is a humanized anti-PD1 IgG4 monoclonal antibody.
Esophageal Cancer
DRUG: Camrelizumab|DRUG: Paclitaxel|DRUG: Cisplatin|DRUG: Placebo|RADIATION: Radiation
PFS assessed by IRC, based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), up to 3 years
PFS assessed by investigators, based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), up to 3 years|OS, OS is defined as the time from registration to death due to any cause, or censored at date last known alive. Measured by the method of Kaplan and Meier., up to 3 years|ORR, based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), up to 3 years|DoR, based on response evaluation criteria in solid tumors 1.1 (RECIST 1.1), up to 3 years|AE, adverse events, up to 3 years
In this study, eligible subjects will be randomized into study arm or control arm. Participants receive camrelizumab or placebo + chemotherapy + radiation therapy . The chemotherapy regimens are : paclitaxel plus cisplatin Progression-free survival (PFS) assessed by the Independent Review Committee (IRC) will be the primary outcomes.